Results 21 to 30 of about 51,024 (230)

A literature review of liver function test elevations in rifampin drug–drug interaction studies

Clinical and Translational Science, 2022
Although rifampin drug–drug interaction (DDI) studies are routinely conducted, there have been instances of liver function test (LFT) elevations, warranting further evaluation.
Sherry M. Ibrahim, Yazdi K. Pithavala, Manoli Vourvahis, Joseph Chen   +3 more
doaj   +1 more source

Effect of the nanoliposomal formulations of rifampin and N-acetyl cysteine on staphylococcus epidermidis biofilm [PDF]

Nanomedicine Journal, 2020
Objective(s): Staphylococcus epidermidis is a common cause of medical device-associated infections due to biofilm formation, and its elimination is extremely challenging. Although rifampin efficacy against S.
Farzaneh Bazrgari, Bahman Khameneh, Bibi Sedigheh Fazly Bazzaz, Asma Mahmoudi, Bizhan Malaekeh-Nikouei   +4 more
doaj   +1 more source

Staphylococcal response to daptomycin in implant-associated infections [PDF]

, 2011
The use of medical devices carries the risk of infection. Due to the development of multi-resistant bacteria, missing microcirculation, and biofilm embedded bacteria these implant-associated infections are difficult to treat.
John, Anne-Kathrin
core   +1 more source

Influence of Rifampin Therapy on Serum Bactericidal Activity in the Presence of Cloxacillin and Vancomycin

Canadian Journal of Infectious Diseases, 1990
In this study the effect of rifampin on serum inhibitory and serum bactericidal titres was examined. Sera were prepared from pooled human serum to contain vancomycin (10 mg/L), cloxacillin (5 mg/L) or rifampin (1 mg/L), and the combinations cloxacillin ...
Andrew MR Mackenzie, Noni E MacDonald
doaj   +1 more source

Malabsorption of Rifampin and Isoniazid in HIV-Infected Patients With and Without Tuberculosis [PDF]

, 2004
The absorption of rifampin, isoniazid, and D-xylose in patients with human immunodeficiency virus (HIV) infection and diarrhea, in patients with HIV infection and tuberculosis (TB), in patients with pulmonary TB alone, and in healthy subjects was ...
Gurumurthy, Prema, Sekar, L., Venkatesan, P, Krishnarajasekhar, O R, Krishnarajasekhar, O. R., Padmapriyadarshini, C, Venkatesan, P., Hemanth Kumar, A K, Padmapriyadarsini, C., Hemanth Kumar, A. K., Paramesh, P., Paramesh, P, Rajasekaran, S., Ramachandran, Geetha, Sekar, L, Swaminathan, Soumya, Kumar, S, Kumar, S., Rajasekaran, S   +18 more
core   +2 more sources

Characterization ofthe Rifampin ADP-ribosyl transferase Enzyme [PDF]

, 2006
The ansamycin antibiotics are unique antibacterial agents that inhibit bacterial DNAdependent RNA polymerase II. Clinical use of this class of antibiotics has primarily been focused on the treatment oftuberculosis using the semi-synthetic rifamycin ...
Baysarowich, Jennifer
core   +1 more source

Role of Rifampin against Staphylococcal Biofilm Infections , in Animal Models, and in Orthopedic-Device-Related Infections. [PDF]

, 2019
Rifampin has been used as an agent in combination therapy in orthopedic device-related infections (ODRI) for almost three decades. The aim of this review is to provide data regarding the role of rifampin against biofilm infection , in animal models, and ...
Sendi, Parham, Zimmerli, Werner
core   +1 more source

Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor

Scientific Reports, 2022
Milvexian (BMS-986177/JNJ-70033093) is a potent, oral small molecule that inhibits the active form of factor XI with high affinity and selectivity.
Vidya Perera, Zhaoqing Wang, Susan Lubin, Lisa J. Christopher, Wei Chen, Sophia Xu, Dietmar Seiffert, Mary DeSouza, Bindu Murthy   +8 more
doaj   +1 more source

Myelosuppression Rates with Administration of Nafcillin with and without Rifampin in Pediatric Patients

Pediatric Reports, 2022
Myelosuppression, a potential adverse reaction of nafcillin and rifampin, is rarely documented in pediatric populations. The objective of this study is to describe the incidence of myelosuppression in pediatric patients receiving nafcillin or a ...
Jolly Kuriakose, Michelle Kaplansky, Caroline M. Sierra   +2 more
doaj   +1 more source

Implant Removal in the Management of Prosthetic Joint Infection by Staphylococcus aureus: Outcome and Predictors of Failure in a Large Retrospective Multicenter Study

Antibiotics, 2021
Objectives: To compare the characteristics and outcomes of cases with acute prosthetic joint infection (PJI; early post-surgical or hematogenous) by Staphylococcus aureus managed with implant removal (IRm) or debridement and retention (DAIR).
Joan Gómez-Junyent, Jaime Lora-Tamayo, Josu Baraia-Etxaburu, Mar Sánchez-Somolinos, Jose Antonio Iribarren, Dolors Rodriguez-Pardo, Julia Praena-Segovia, Luisa Sorlí, Alberto Bahamonde, Melchor Riera, Alicia Rico, Mª Dolores del Toro, Laura Morata, Javier Cobo, Luis Falgueras, Natividad Benito, Elena Muñez, Alfredo Jover-Sáenz, Carles Pigrau, Javier Ariza, Oscar Murillo   +20 more
doaj   +1 more source